Background: Occult breast carcinoma is occasionally found in reduction mammaplasty specimens. Historically, these patients were treated with mastectomy because the exact location of the tumor was unknown. Currently, breast conservation is the treatment of choice in 50 to 85 percent of breast cancers. The authors present a technique of routine specimen marking that allows localization of the tumor and preservation of the choice of lumpectomy. Methods: This is a retrospective review of 866 patients who underwent reduction mammaplasty performed by a single surgeon between 1990 and 2009. Data were collected for patients who had occult cancer found in their specimens, including age, cancer risk factors, abnormality, nodal status, selected treatment, and survival status. Specimens were marked and oriented and then sent in separate bags to the pathologist. Results: There were 10 cases of occult carcinoma among the 866 women (1.15 percent) who underwent reduction mammaplasty. Six cancers were found in patients undergoing reduction for symptomatic macromastia [n ϭ 629 (0.95 percent)]. Four new cancers were found in the group of patients with a personal history of cancer [n ϭ 237 (1.69 percent)]. All 10 patients had normal preoperative mammograms. Location, size, and margin status were easily identified and patients were offered the choice of lumpectomy or mastectomy. Conclusions: This article demonstrates that careful marking of reduction specimens in high-risk patients or in women older than 40 years allows the pathologist to orient, localize, and further section tissue for margin status. Communication among plastic surgeon, pathologist, oncologist, and radiation therapist preserves the choice of breast conserving therapy for early cancers. (Plast. Reconstr. Surg. 127: 525, 2011.) 
A
ccording to the American Society of Plastic Surgeons, nearly 90,000 women in the United States underwent reduction mammaplasty in 2008. 1 The American Cancer Society surveillance study found 192,370 new cases of breast cancer in 2009 2 ; thus, it is not surprising that some patients undergoing breast reduction will have the unsuspected finding of carcinoma. Indeed, some reduction patients have a history of prior biopsies or positive family histories, whereas other patients have a known history of breast cancer and are undergoing symmetry operations on the contralateral breast. Unsuspected carcinoma in breast reduction specimens is reported to be between 0.06 and 4 percent (Tang et al., 3 0.06 percent; Jansen et al., 4 0.16 percent; Dotto et al., 5 0.38 percent; Colwell et al., 6 0.8 percent; Kakagia et al., 7 0.95 percent; Clark et al., 8 1.1 percent; Viana et al., 9 1.7 percent; and Ambaye et al., 10 4 percent). The reported occurrence of occult cancer in the opposite breast of a patient with known breast cancer is between 3 and 7 percent (Bernard et al., 11 3.8 percent; Petit et al., 12 4.6 percent; Ricci et al., 13 4.4 percent; Renz et al., 14 4.8 percent; and Wright et al., 15 7 percent). A tumor found incidentally in a breast reduction specimen may obligate mastectomy to ensure adequate treatment if the location and margin status are not known.
Twenty years ago, mastectomy was the treatment for breast cancer; thus, patients with occult cancer found at reduction mammaplasty did not receive different treatment. Today, options for treatment of breast cancer have expanded. Fifty to 80 percent of breast cancer patients are treated with lumpectomy and irradiation, and 80 percent of patients are candidates for lumpectomy. 16, 17 The long-term survival of lumpectomy and irradiation as compared with mastectomy is the same. 18 If the location, size, and margin status of tumors found in reduction specimens were known, patients could be offered the option of lumpectomy with irradiation or mastectomy. Unfortunately, even recent reports of occult cancers treat these generally early lesions with mastectomy. Clark et al. 8 reported on 562 consecutive reductions in which six patients were found to have ductal carcinoma in situ (1.1 percent). They state that "five patients underwent completion mastectomy. One patient with ductal carcinoma in situ declined mastectomy and underwent radiation." Golshan et al. 19 reported on six patients who had skin-sparing mastectomies after finding carcinoma in reduction specimens. They stated "we do not feel that breast conservation should be an option for these patients because of the nature of the specimens and the lack of orientation." Rudolph and Niedbala 20 reported two patients with occult carcinoma identified in specimens following reduction mammaplasty and both went on to mastectomy. The authors state that "the unmarked and therefore, uncertain location on the tumor margins excluded breast conservation surgery as a treatment option for both our patients." Butler et al. 21 reported finding a contralateral cancer and state that "when a tumor is found postoperatively on permanent section, the treatment options are limited as a result of the widely exposed breast tissue planes and difficulty ascertaining the exact location of the tumor." We present a simple system of side and quadrant marking that permits breast-conserving treatment should an occult tumor be identified in the reduction specimen.
PATIENTS AND METHODS
We conducted an institutional review boardapproved retrospective chart review of 866 female patients who underwent reduction mammaplasty performed between 1990 and 2009 by a single surgeon (S.S.). Ten patients were identified who had occult cancer (ductal carcinoma in situ, invasive lobular or invasive ductal carcinoma) in their reduction specimens. Patients in whom atypical hyperplasia or lobular carcinoma in situ was found were not included as having occult cancers because these are high-risk markers only. Data collected included age, prior diagnosis of breast cancer, risk factors, mammogram results, pathologic findings of reduction specimen, nodal status, treatment of occult carcinoma, and survival outcome. All reductions were performed with either the McKissock bipedicled or the amputation free nipple graft method. Three specimens were sent from each breast: central, medial, and lateral. Each specimen consisted of a solid piece of tissue, clearly labeled, oriented, and sent for pathologic evaluation in a separate bag (Fig. 1 ). The medial and medial superior breast was resected as one specimen with skin attached on the inferior portion, which helped give orientation to the tissue. The lateral and lateral superior quadrant were similarly resected. The central pedicle was taken above the areola. A single stitch, staple, cautery mark, or marking pen dot was placed on the most anterior and superior point of each individual piece (Fig. 2) .
Routine pathologic examination of breast tissue was performed on each specimen. The tissue was cut grossly at 4-to 10-mm intervals, 22 depending on the fat content of the breast. Any suspicious lesion was fixed. If there were no suspicious lesions, two to four representative slides were made of the white fibrous breast tissue. When an occult lesion was found, as was the case in our 10 patients, the tissue was reexamined with additional cuts 2 to 4 mm apart. The tumor was located by quadrant. It was either at a cut margin or contained within the tissue, and the distance to the cut margin was recorded. Size of the tumor was determined by the number of cuts that the tumor appeared in, and 
RESULTS
Occult carcinoma was identified in 10 of the 866 patients (1.15 percent) ( Table 1 ). In patients undergoing reduction for symptomatic macromastia and with no prior cancer history (n ϭ 629), six cancers were found, for an incidence of 0.95 percent. In the group of patients with a personal history of cancer (n ϭ 237), four new cancers were found, for an incidence of 1.69 percent. All patients were women, and the age range for the occult cancers was 42 to 72 years. All of these patients undergoing reduction for symptomatic macromastia with no prior breast abnormality (n ϭ 6) had normal preoperative mammograms. Four patients had known histories of cancer or breast abnormality and were undergoing symmetry operations or reduction following lumpectomy. In these patients, the preoperative mammogram on the breast to be reduced was normal.
Of the 10 patients with occult carcinoma, one patient had disease in both breasts and in multiple quadrants and needed bilateral mastectomies. The other nine patients were presented at multidisciplinary rounds and pathologic data were reviewed. All of these patients (n ϭ 9) were offered breast conservation for these early cancers. One patient had a sister with breast cancer and elected to have bilateral mastectomies and reconstruction. Two patients underwent surgical reexcision of margins. In one patient, the margins were clear; in the other patient, the margins were again positive and she underwent mastectomy. Six of the patients were considered to have adequate resection and needed only irradiation or antiestrogens. Nodal examination of these patients was dictated by the multidisciplinary recommendations. Treatment varied from no treatment to sentinel node or axillary dissection. Recent studies show that sentinel node mapping remains accurate despite prior surgery. 23 Follow-up of those diagnosed with occult carcinoma ranged from 1 to 12 years. All are currently disease free. Only one patient had subsequent cancer found during the follow-up period. Her follow-up mammogram at 4 years after reduction showed new calcifications in the involved breast, and biopsy revealed ductal carcinoma in situ. The patient then elected to have bilateral mastectomies and is disease free at 9 years.
DISCUSSION
Routine pathologic examination of breast specimens is controversial. Many plastic surgeons send their specimens to the pathology department as "left" and "right" in two separate containers. More specific labeling of specimens allows the pathologist to orient, localize, and further section tissue with tumor. Labeling can be easily accomplished by marking a standard point with suture, marking dyes, staples, or cautery marks. Overlying skin also helps in orientation. Placement of the specimens in three different bags per breast dictates that each quadrant is examined and sectioned by the pathologist. Ambaye et al. 10 found that increased sampling leads to increased detection of abnormality. These authors found that the study of an additional one or two areas of breast reduction specimens in women older than 40 identified more cancers. However, additional pathologic examination also incurred more cost.
Other surgeons feel that reduction specimen screening is not accurate or cost-effective. Tissue screening of reduction specimens is a significant challenge for the pathologist. 24 Most ductal carcinoma in situ is not visible on gross examination. Only a small percentage of all tissue from breast reduction specimens can be examined, as total examination would entail hundreds of tissue blocks from each case. The Royal College of Pathologists 25 concluded that random sampling of macroscopically normal tissue from breast reduction specimens was of "limited clinical value," after Cook and Fuller 26 found ductal carcinoma in situ or invasive cancer in 0.4 percent of patients undergoing breast reduction surgery. Olack et al. 27 conducted a study to determine the cost-effectiveness of routine pathologic examination of specimens from reduction mammaplasty and, more specifically, cost savings if only specimens from women older than 40 years were submitted. They found that 20 percent of moderate-to high-risk abnormality would have been missed, at a savings of $654.00 per patient.
Preoperative mammography is a more practical and cost-effective way of excluding occult malignancy in patients undergoing reduction mammaplasty. Routine mammography before breast reduction in women older than 40 years is recommended by the American Cancer Society 28 and the American Congress of Obstetricians and Gynecologists. 29 However, the U.S. Preventive Services Task Force recommends against routine screening mammography in women aged 40 to 49 years and advocates biennial screening mammography for women aged 50 to 74 years. 30 There is a wide variation of practice for women in the age range of 30 to 39 years, especially those considering breast surgery. It is generally recommended that women who are at higher risk for breast cancer should talk with their health care providers about having mammograms before age 40 and how often to have them. It is as yet unknown whether magnetic resonance imaging would be a useful adjunct in these patients. 31 Occult breast cancer is a rare but real risk of reduction mammaplasty. Some patients with previous cancer or risk factors are particularly at risk. As a result of our experience, we recommend careful marking of reduction specimens. All patients older than 40 years or those with a family history and older than 35 years should have preoperative mammograms. Should a visible abnormality be found at operation, a frozen section can be obtained and the location marked. Formal margins can be obtained. In a routine reduction, we mark each quadrant with a suture, marking pen, cautery, or staple such that orientation could be determined if a pathologic diagnosis of cancer is unexpectedly encountered. If carcinoma is found in the reduction specimen, the surgeon should confer with the pathologist and explain the reduction pattern and orientation of the specimen. Multidisciplinary breast conferences can be used to gain consensus on treatment. Communication among plastic surgeon, pathologist, oncologist, and radiation therapist can allow women to preserve the choice of lumpectomy for these early cancers. In our experience, after recovering from the initial shock of the diagnosis, patients are extremely grateful that options for treatment have been preserved and that a tumor has been found at an early stage.
CONCLUSIONS
Ten occult carcinomas were found in 866 reduction mammaplasties, for an incidence of 1.15 percent. Four unexpected cancers were found in 237 patients with a known cancer diagnosis (1.69 percent), and six of 629 patients undergoing reduction for macromastia symptoms had occult cancer (0.95 percent). Because each reduction specimen was marked for orientation, the location, size, and margin status could be evaluated. Patients were discussed at multidisciplinary breast conferences, and treatment recommendations were discussed with the patient. Patients had the option of lumpectomy or mastectomy. Seven patients chose breast conservation.
